FindTrial
Sign In

Cisplatin 1mg/ml Injection BP

DRUG3 trials

Sponsors

AbbVie Deutschland GmbH & Co. KG, Genmab A/S

Conditions

Advanced or Metastatic Non-Squamous NSCLCMalignant solid tumors: endometrial carcinoma (EC)Untreated Metastatic Non-Squamous Non-Small Cell Lung Canceror cervical cancer.squamous cell carcinoma of the head and neck (SCCHN)triple-negative breast cancer (TNBC)urothelial carcinoma (UC)

Phase 1

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Active, not recruitingCTIS2023-509059-15-00
Genmab A/SMalignant solid tumors: endometrial carcinoma (EC), or cervical cancer., squamous cell carcinoma of the head and neck (SCCHN) +2
Start: 2019-04-30Target: 295Updated: 2026-01-16
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536)
RecruitingCTIS2024-514465-18-00
AbbVie Deutschland GmbH & Co. KGAdvanced or Metastatic Non-Squamous NSCLC
Start: 2025-04-23Target: 105Updated: 2025-11-27

Phase 2

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
RecruitingCTIS2023-505773-32-00
AbbVie Deutschland GmbH & Co. KGUntreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Start: 2025-03-25Target: 57Updated: 2025-11-21